Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARTL 
Artelo Biosciences Inc (ARTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ARTL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18
1 Year Target Price $18
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.14% | Avg. Invested days 28 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.95M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 2 | Beta 1.36 | 52 Weeks Range 4.92 - 28.60 | Updated Date 08/28/2025 |
52 Weeks Range 4.92 - 28.60 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -18.93 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.13 | Actual -5.61 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -103.84% | Return on Equity (TTM) -356.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10705968 | Price to Sales(TTM) - |
Enterprise Value 10705968 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.22 | Shares Outstanding 1321550 | Shares Floating 1317098 |
Shares Outstanding 1321550 | Shares Floating 1317098 | ||
Percent Insiders 0.34 | Percent Institutions 1.6 |
Upturn AI SWOT
Artelo Biosciences Inc
Company Overview
History and Background
Artelo Biosciences Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics that modulate the endocannabinoid system. Founded in 2011, it has focused on developing novel compounds for various diseases.
Core Business Areas
- Fatty Acid Binding Protein 5 (FABP5) Inhibitors: Development of inhibitors targeting FABP5, which is involved in cancer, pain, and anxiety.
- GPCR Modulators: Development of small molecule GPCR modulators to target cannabinoid receptors for various therapeutic applications.
Leadership and Structure
Gregory D. Gorgas serves as the Chief Executive Officer. The company has a scientific advisory board and is structured as a typical publicly traded biopharmaceutical company.
Top Products and Market Share
Key Offerings
- ART27.13: A small molecule modulator of G protein-coupled receptor 119 (GPR119) that is being developed for cancer-related anorexia. Currently undergoing clinical trials. Competitors in cancer anorexia include pharmaceutical companies developing appetite stimulants like megestrol acetate and dronabinol.
- ART26.12: A Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed for pain and anxiety. Currently in preclinical stages. Competitors include companies developing novel pain medications and anxiety treatments.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated, with a focus on innovation and clinical trial success. The endocannabinoid system is a target for various therapeutic areas.
Positioning
Artelo Biosciences Inc. is a niche player focused on the endocannabinoid system, differentiating itself through its unique drug candidates and targeting specific unmet medical needs.
Total Addressable Market (TAM)
The total addressable market for cancer anorexia and pain management is significant, potentially reaching billions of dollars. Artelo is positioned to capture a portion of this market if their drugs are successful.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting the endocannabinoid system
- Focus on unmet medical needs
- Experienced management team
- Intellectual property protection
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Small market capitalization
- Early stage development
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive regulatory outcomes
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- GWPH
- ABBV
- CRBP
Competitive Landscape
Artelo faces intense competition from larger, more established pharmaceutical companies. Its success depends on demonstrating the superiority of its novel drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Limited historical revenue growth due to the company's focus on R&D.
Future Projections: Future growth hinges on clinical trial results and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Focusing on advancing its lead drug candidates through clinical trials and exploring strategic partnerships.
Summary
Artelo Biosciences Inc. is a high-risk, high-reward biopharmaceutical company with a focus on the endocannabinoid system. Its success is contingent on the positive outcomes of its clinical trials and its ability to secure funding. While the company has novel drug candidates, it faces significant competition and financial challenges. ARTL is dependent on strong positive data from their clinical trials to demonstrate the usefulness and safety of their product candidates.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information contained herein may not be accurate or complete. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Artelo Biosciences Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2017-11-14 | President, CEO, Treasurer, Secretary & Director Mr. Gregory D. Gorgas M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.artelobio.com |
Full time employees 5 | Website https://www.artelobio.com | ||
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated/ weight loss with cancer; and ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, pain and inflammation, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.